Tap Boston Scientific’s bright future

Article Excerpt

There’s little doubt that the developing world’s aging population will help drive up global spending on medical services in the years to come. Medical device makers, however, are also well positioned to capture a share of that increased spending. We continue to see attractive investment opportunities for our subscribers among the top device manufacturers—and that includes Boston Scientific. We recommend this stock as a Power Buy. BOSTON SCIENTIFIC CORP., $37.50, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (www.bostonscientific.com; Shares outstanding: 1.4 billion; Market cap: $54.3 billion; No dividends paid) develops and markets medical devices used in minimally invasive procedures. Its products are used for angioplasty (blood vessel repair), blood clot filtration, cardiac rhythm management, catheter-aided ultrasound imaging, and many other surgical procedures. It generates 58% of its sales in the U.S. and 42% internationally. In the three months ended December 31, 2020, Boston Scientific’s revenues declined 6.8%, to $2.71 billion from $2.91 billion a year earlier. Like other industry suppliers, Boston Scientific was…